HBM HOLDINGS-B (02142.HK): CRHX-101 Spin-Off Targets Nasdaq Listing

On 18 November 2026, HBM HOLDINGS-B (02142.HK) said Spruce spun CRHX-101 into new unit Adrenyx, which plans a Nasdaq listing in the first half of 2027.

NewTimeSpace News: On 18 November 2026, HBM Holdings Limited (stock code: 02142) said on a voluntary basis that its partner Spruce Biosciences Inc. (Nasdaq: SPRB) has spun off its CRHX-101 programme, also known as HBM9013/HAT001/SPR-202, into a newly incorporated wholly-owned subsidiary, Adrenyx Biosciences, Inc. Adrenyx is expected to list on Nasdaq in the first half of 2027. Once the pro-rata distribution of Adrenyx shares to Spruce shareholders is completed, HBM expects to hold equity interests in both Spruce and Adrenyx.

CRHX-101 is a monoclonal antibody designed and developed for the treatment of congenital adrenal hyperplasia. Adrenyx intends to file an investigational new drug application with the US Food and Drug Administration for CRHX-101 and thereafter initiate clinical development.

The programme originated from HBM Alpha Therapeutics, a majority-owned subsidiary of HBM. In January 2025, that subsidiary entered into a collaboration and licence agreement with Spruce, granting Spruce exclusive global rights to develop and commercialise CRHX-101 outside Greater China, comprising mainland China, Taiwan, Hong Kong and Macao. Further details are set out in the company's announcement dated 26 February 2025.

The company issued the warning statement required under Rule 18A.05 of the Listing Rules: neither the company nor any of its partners guarantees that any product mentioned in the announcement will ultimately be successfully developed and marketed. The company advised shareholders and potential investors to exercise caution when dealing in its shares.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.